Engineered Ultrasmall Nanoparticle Drug‐Immune Conjugates with "Hit and Run" Tumor Delivery to Eradicate Gastric Cancer (Adv. Therap. 3/2023). Issue 3 (10th March 2023)

• Record Type: Journal Article
• Authors: Zhang, Li; Aragon‐Sanabria, Virginia; Aditya, Anusha; Marelli, Marcello; Cao, Tianye; Chen, Feng; Yoo, Barney; Ma, Kai; Zhuang, Li; Cailleau, Thais; Masterson, Luke; Turker, Melik Z.; Lee, Rachel; DeLeon, Gabriel; Monette, Sebastien; Colombo, Raffaele; Christie, Ronald J.; Zanzonico, Pat; Wiesner, Ulrich; Subramony, J. Anand; Bradbury, Michelle S.
• Is Part Of: Advanced therapeutics. Volume 6:Issue 3(2023)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2023-03-10
• Subjects: Therapeutics -- Periodicals; Pharmaceutical technology -- Periodicals; Pharmacogenetics -- Periodicals; 615.5
• DOI: 10.1002/adtp.202370009
• Languages: English
• ISSNs: 2366-3987

Abstract

Abstract : Receptor‐mediated endocytosis of a precision engineered HER2‐targeting ultrasmall silica nanoparticle drug conjugate after binding the HER2 extracellular domain on gastric cancer cells. This is reported by Ulrich Wiesner, J. Anand Subramony, Michelle S. Bradbury, and co‐workers in article number 2200209 .